Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1993 1
1994 3
1999 1
2002 1
2003 1
2012 1
2013 2
2017 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses.
Serrano-Rodríguez JM, Gómez-Díez M, Esgueva M, Castejón-Riber C, Mena-Bravo A, Priego-Capote F, Ayala N, Caballero JMS, Muñoz A. Serrano-Rodríguez JM, et al. Res Vet Sci. 2017 Oct;114:117-122. doi: 10.1016/j.rvsc.2017.03.016. Epub 2017 Mar 28. Res Vet Sci. 2017. PMID: 28371693 Clinical Trial.
Pharmacokinetic and pharmacodynamic (PK/PD) properties of the angiotensin-converting enzyme inhibitor (ACEI) benazeprilat have not been evaluated in horses. This study was designed to establish PK profiles for benazepril and benazeprilat after intravenous (IV) and o …
Pharmacokinetic and pharmacodynamic (PK/PD) properties of the angiotensin-converting enzyme inhibitor (ACEI) benazeprilat have not be …
An angiotensin converting enzyme inhibitor, benazepril can be transformed to an active metabolite, benazeprilat, by the liver of dogs with ascitic pulmonary heartworm disease.
Kitagawa H, Ohba Y, Kuwahara Y, Ohne R, Kondo M, Nakano M, Sasaki Y, Kitoh K. Kitagawa H, et al. J Vet Med Sci. 2003 Jun;65(6):701-6. doi: 10.1292/jvms.65.701. J Vet Med Sci. 2003. PMID: 12867730 Clinical Trial.
In 7 dogs with ascitic pulmonary heartworm disease, plasma benazeprilat concentrations tended to be higher than in 7 control dogs both on the 1st and 7th administration days. ...In dogs with ascitic heartworm disease, benazepril was readily transformed to benazeprilat …
In 7 dogs with ascitic pulmonary heartworm disease, plasma benazeprilat concentrations tended to be higher than in 7 control dogs bot …
Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects.
Sun JX, Cipriano A, Chan K, John VA. Sun JX, et al. Eur J Clin Pharmacol. 1994;47(3):285-9. doi: 10.1007/BF02570510. Eur J Clin Pharmacol. 1994. PMID: 7867683 Clinical Trial.
Serial blood samples were collected following each administration for the determination of benazepril and its active metabolite benazeprilat and amlodipine. The mean values of AUC (0-4 h), Cmax and Tmax for benazepril given as combination versus given alone were 161 vs 140 …
Serial blood samples were collected following each administration for the determination of benazepril and its active metabolite benazepri …
Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats.
King JN, Strehlau G, Wernsing J, Brown SA. King JN, et al. J Vet Pharmacol Ther. 2002 Oct;25(5):371-8. doi: 10.1046/j.1365-2885.2002.00427.x. J Vet Pharmacol Ther. 2002. PMID: 12423228 Clinical Trial.
The active metabolite of benazepril, benazeprilat, is eliminated principally ( approximately 85%) via biliary excretion in cats. ...There were no significant differences in SBP, DBP, MBP, benazeprilat or ACE values according to the degree of renal insufficiency in c …
The active metabolite of benazepril, benazeprilat, is eliminated principally ( approximately 85%) via biliary excretion in cats. ...T …
The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril.
Macdonald NJ, Sioufi A, Howie CA, Wade JR, Elliott HL. Macdonald NJ, et al. Br J Clin Pharmacol. 1993 Sep;36(3):205-9. doi: 10.1111/j.1365-2125.1993.tb04218.x. Br J Clin Pharmacol. 1993. PMID: 9114905 Free PMC article. Clinical Trial.
The hypotensive effect was similar after both drugs but the absolute reductions were greater in the elderly who had higher initial levels of blood pressure. 3. The AUCs for both benazeprilat and enalaprilat were higher in the elderly but by a significantly greater amount f …
The hypotensive effect was similar after both drugs but the absolute reductions were greater in the elderly who had higher initial levels of …
Bioequivalence of a new liquid formulation of benazepril compared with the reference tablet product.
Kelers K, Devi JL, Anderson GA, Zahra P, Vine JH, Whittem T. Kelers K, et al. Aust Vet J. 2013 Aug;91(8):312-9. doi: 10.1111/avj.12080. Aust Vet J. 2013. PMID: 23889096 Clinical Trial.
Blood samples taken prior to treatment and serially after treatment were analysed for plasma concentrations of benazepril and benazeprilat and the activity and concentration of angiotensin-converting enzyme (ACE). The calculated percentage inhibition of ACE was defined as …
Blood samples taken prior to treatment and serially after treatment were analysed for plasma concentrations of benazepril and benazeprila …
Adenosine causes the release of active renin and angiotensin II in the coronary circulation of patients with essential hypertension.
Virdis A, Ghiadoni L, Marzilli M, Orsini E, Favilla S, Duranti P, Taddei S, Marraccini P, Salvetti A. Virdis A, et al. J Am Coll Cardiol. 1999 May;33(6):1677-84. doi: 10.1016/s0735-1097(99)00078-9. J Am Coll Cardiol. 1999. PMID: 10334442 Free article. Clinical Trial.
In five out of 12 hypertensive patients adenosine infusion and plasma samples were repeated during intracoronary angiotensin-converting enzyme inhibitor benazeprilat (25 microg/min) administration. Finally, in adjunctive hypertensive patients, the same procedure was applie …
In five out of 12 hypertensive patients adenosine infusion and plasma samples were repeated during intracoronary angiotensin-converting enzy …
Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs.
Mochel JP, Peyrou M, Fink M, Strehlau G, Mohamed R, Giraudel JM, Ploeger B, Danhof M. Mochel JP, et al. J Vet Pharmacol Ther. 2013 Apr;36(2):174-80. doi: 10.1111/j.1365-2885.2012.01406.x. Epub 2012 May 8. J Vet Pharmacol Ther. 2013. PMID: 22568394 Clinical Trial.
Results indicated substantial changes in the dynamics of these biomarkers. At presumed benazeprilat steady state, significant differences in AUC of plasma renin activity (+90%), angiotensin I (+43%), and AII (-53%) were found between benazepril and placebo-treated dogs. .. …
Results indicated substantial changes in the dynamics of these biomarkers. At presumed benazeprilat steady state, significant differe …
Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers.
Chan KK, Buch A, Glazer RD, John VA, Barr WH. Chan KK, et al. Pharm Res. 1994 Mar;11(3):432-7. doi: 10.1023/a:1018925407109. Pharm Res. 1994. PMID: 8008712 Clinical Trial.
Serial plasma and urine samples were collected for up to 4 days after dosing. BZPH and its active metabolite benazeprilat (BZPL) were determined using a gas chromatography/mass spectrometry method. BZPH was absorbed rapidly into the bloodstream (Tmax = 0.5 hr after ORAL). …
Serial plasma and urine samples were collected for up to 4 days after dosing. BZPH and its active metabolite benazeprilat (BZPL) were …
The absence of a pharmacokinetic interaction between aspirin and the angiotensin-converting enzyme inhibitor benazepril in healthy volunteers.
Sioufi A, Pommier F, Gauducheau N, Godbillon J, Choi L, John V. Sioufi A, et al. Biopharm Drug Dispos. 1994 Aug;15(6):451-61. doi: 10.1002/bdd.2510150603. Biopharm Drug Dispos. 1994. PMID: 7993983 Clinical Trial.
Plasma concentration profiles of benazepril, its active metabolite benazeprilat, and total salicylic acid were determined together with urinary excretion of benazeprilat, salicylic acid, salicyluric acid, and salicylate glucuronides. Almost superimposable plasma pro …
Plasma concentration profiles of benazepril, its active metabolite benazeprilat, and total salicylic acid were determined together wi …
11 results